Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT06149689

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

Led by Fudan University · Updated on 2025-08-07

30

Participants Needed

1

Research Sites

146 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer.

CONDITIONS

Official Title

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand and willing to sign informed consent
  • Age between 18 and 80 years
  • ECOG performance status of 0 to 2
  • Histologically or cytologically confirmed advanced pancreatic adenocarcinoma
  • No prior anti-tumor therapy received
  • Baseline serum CA19-9 4 U/mL, CEA 5.2 ng/mL, and CA125 5 U/mL
  • At least one measurable lesion based on RECIST criteria
  • Expected survival of at least 3 months
  • Adequate organ function based on blood tests
  • Women of childbearing potential and men agree to use effective contraception throughout the study
Not Eligible

You will not qualify if you...

  • Pregnant or nursing women
  • Previous anti-tumor therapy received
  • Baseline serum CA19-9 above 37 U/mL, CEA above 5.2 ng/mL, or CA125 above 35 U/mL
  • Diagnosis confirmed as non-adenocarcinoma of the pancreas
  • Inflammation of the digestive tract such as pancreatitis, cholecystitis, or cholangitis
  • Severe or uncontrolled diseases affecting compliance or result interpretation
  • Renal insufficiency or dialysis
  • Other serious illnesses that may affect treatment safety
  • Allergy to oxaliplatin or other chemotherapy drugs
  • Unwillingness or inability to follow study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Cancer Center

Shanghai, China

Actively Recruiting

Loading map...

Research Team

Y

Ying Yang, MD

CONTACT

G

Guopei Luo, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer | DecenTrialz